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Prostaglandin E2 receptors in abdominal aortic
aneurysm and human aortic smooth muscle cells
T. Bayston, S. Ramessur, J. Reise, K. G. Jones, and J. T. Powell, London, United Kingdom
Background: Prostaglandin (PG) E2 (PGE2) appears to have a role in stimulating production of interleukin-6 (IL-6) and
apoptosis of smooth muscle cells in diseased aortic tissue. These actions are mediated by cellular receptors for PGE2 EP
receptors.
Objective: This study was undertaken to identify EP receptors associated with production of IL-6 by aortic explants.
Methods: Biopsy specimens of abdominal aortic aneurysm were used for explant culture and preparation of messenger
RNA. The presence of EP1, EP2, EP3, and EP4 receptors in tissue and cells was investigated with reverse-transcriptase
polymerase chain reaction. IL-6 and cyclic adenosine monophosphate were measured with an enzyme-linked immunosor-
bent assay.
Results: PGE2 or 11-deoxy-PGE1 (EP 2/3/4 agonist) reversed partially the indomethacin suppression of IL-6 secretion
from explant cultures, whereas butaprost (EP2 receptor agonist) and sulprostone (EP 1/3 receptor agonist) had no
effect. Aortic biopsy specimens expressed EP2, EP3-III, and EP4 receptors. Aortic smooth muscle cells expressed EP2
receptor and four variants of EP3 receptor, ie, EP3-Ib, EP3-II, EP3-III, and EP3-IV, but PGE2 did not stimulate
secretion of IL-6. In contrast, PGE2 or 11-deoxy-PGE1 stimulated secretion of IL-6 from aortic macrophages.
Conclusions: In aortic explants, PGE2 stimulates IL-6 secretion by activation of EP4 receptors, present in macrophages.
(J Vasc Surg 2003;38:354-9.)
Prostaglandin (PG) E2 has a wide range of pathophys-
iologic effects, including contraction and relaxation of vas-
cular smooth muscle, modulation of inflammatory pro-
cesses, and connective tissue turnover.1-3 PGE2 is
synthesized in high volume in diseased aorta, eg, with
stenosis or aneurysm.4-6 There is some evidence to suggest
that PGE2 and other cyclooxygenase products contribute
to the pathologic processes that underlie expansion of
abdominal aortic aneurysm (AAA). First, indomethacin
inhibits expansion of experimental AAA by inhibition of
cyclooxygenase 2 (COX2), with resultant decrease in PGE2
and matrix metalloproteinase-9 (MMP-9).6 Second, indo-
methacin suppresses secretion of inflammatory mediators
from AAA tissue, effects that are partially reversible with
exogenous PGE2.
5 Third, nonsteroidal anti-inflammatory
drugs may have some effect to reduce AAA expansion rates
in human beings.5 The actions of PGE2 are mediated by an
array of G protein–coupled receptors, with at least four
subtypes, EP1, EP2, EP3, and EP4. Pharmacologic studies
have indicated the presence of EP1, EP2, and EP3 recep-
tors in vascular smooth muscle, although EP1 receptors are
sparse in human tissue.8,9 In addition, EP4 receptor mes-
senger RNA (mRNA) has been detected in cultured human
umbilical vein smoothmuscle cells (SMC),10 and both EP2
and EP4 receptors are present in inflammatory cells.11 The
EP3 receptor is the most complex, with alternate splicing
potentially generating more than seven receptor sub-
types.9-11 These different EP3 receptor subtypes appear to
be coupled to at least three second messenger systems,
usually leading to inhibition of adenylyl cyclase.9-11 The
EP2 receptor is ubiquitous, and, like the EP4 receptor,
couples to activation of adenylyl cyclase and increased
cellular cyclic adenosine monophosphate (cAMP) concen-
tration. In contrast, the EP1 receptor couples to phospho-
lipase C.
The pharmacologic tools for probing the roles of spe-
cific EP receptors are limited. Butaprost is a relatively
selective EP2 receptor agonist; sulprostone is a relatively
selective agonist for EP1 and EP3 receptors; and 11-deoxy-
PGE1 is an agonist for EP2, EP3, and EP4 receptors. We
used these agonists to investigate the role of EP receptors in
stimulating production of interleukin-6 (IL-6) in biopsy
specimens from AAA, and we complemented these studies
with investigation of EP receptor andmRNA expression. In
addition, we listed these same agonists to investigate the EP
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receptors and their subtypes that modulate cAMP synthesis
in aortic SMC. In vascular SMC cells, elevation of cAMP
concentration is associated with inhibition of SMC prolif-
eration.12 In AAA there is evidence of apoptosis and irre-
versible loss of medial aortic SMC, and this process may be
influenced by PGE2.
5,13,14
MATERIALS AND METHODS
Tissues and cells. Biopsy specimens of AAA were
harvested, and explant cultures for analysis of IL-6 secre-
tion and culture of SMC from the medial layer were estab-
lished as described.7 Explants were incubated with these
reagents for 9 hours. Indomethacin and prostaglandins
(PGE2, 11-deoxy-PGE1, butaprost, and sulprostone; all
from Cayman Chemical Co, Ann Arbor, Mich), were pre-
pared in ethanol, and controls included the same amount of
ethanol; dexamethasone was obtained from Charing Cross
Hospital Pharmacy (London, UK). Part of the biopsy sam-
ple was snap-frozen in liquid nitrogen for later isolation of
mRNA. Human aortic SMC from normal aorta were ob-
tained fromCascade Biologics (Portland, Ore) and used up
to passage 6. All human aortic SMC were cultured in
medium 231 (Cascade Biologics). Macrophages were iso-
lated from aortic aneurysm biopsy specimens, as described
previously,5 yield 80 to 130,000 per gram of tissue wet
weight. The HSB-2 cell line was obtained from the Euro-
pean Cell Culture Collection, and suspension cultures were
maintained in RPMI 1640 supplemented with 10% fetal
calf serum. Frozen placenta was a gift fromDr D. Sooranna
(Imperial College). Genomic DNA, prepared from periph-
eral blood cells, was available from several patients with
AAA. Local ethical approval was in place for use of all
human tissue samples.
mRNA isolation and reverse transcription. mRNA
was isolated from cells with the Micro-Fast Track mRNA
Isolation kit (Invitrogen, Carlsbad, Calif), according to the
manufacturer’s instructions. Tissue samples were ground to
a powder in liquid nitrogen before using the same kit to
isolate mRNA. First-strand complementary DNA (cDNA)
was synthesized with the cDNA Cycle Kit (Invitrogen)
according to the manufacturer’s instructions. A 621 base
pair (bp) fragment of the -actin gene was amplified to
confirm successful mRNA extraction and cDNA synthesis
using the primer pair 5'-ATCATGTTTGAGACCTTCAA
CACCCC-3' and 5'-CTTGATCTTCATTGTGCTGGG
TGCCA-3'.
Polymerase chain reaction for EP receptors. Nested
primers for the EP1, EP2, and splice variants of EP3 were
designed with the freeware program Primers (Macintosh,
Redmond, Calif). The primers used are described in Table
I. mRNA from placenta was used to provide a positive
control for EP1, EP2, EP3, and EP4 receptors and from
HSB-2 cells as a positive control for EP3 variants.11,15 All
polymerase chain reactions (PCR) were performed in 10
mmol/L of Tris hydrochloride (pH 9.0), 50 mmol/L of
potassium chloride, 0.1% Triton X-100, 1.5 mmol/L of
magnesium dichloride, 200 mol/L of deoxyribonucleo-
side triphosphate, 10 pmol of primer with 1 unit of Taq
polymerase, in a total reaction volume of 50 L (all re-
agents from Promega [Madison, Wis]). PCR conditions
were denaturation at 94°C for 5 minutes, followed by 30
cycles of denaturation at 94°C for 1 minute, annealing at
50°C for 1 minute, elongation at 72°C for 2 minutes, and
final elongation at 72&degC for 5 minutes. Products were
separated on 2% NuSieve (GTG 3:1)/1  Tris-borate/
EDTA gels containing 1.5 g/mL of ethidium bromide
and visualized with ultraviolet transillumination.
Cloning and sequencing of fragments of the EP3
gene. To confirm the identity of each of the bands found
after reverse transcription (RT) PCR for the EP3 receptor
splice isoforms, the products were cloned into the pCR2.1
vector (Invitrogen), according to the manufacturer’s in-
structions. After ligation and transformation, single colo-
nies were picked and grown at 37°C for 16 hours in 2 mL
of recommended medium with selective antibiotics. One
milliliter of each liquid culture was used with no purifica-
tion as the template in PCR with the internal EP3 primer
pairs. After confirmation with gel electrophoresis that the
clones contained fragments of the expected size, the plas-
mid DNA was purified (Wizard Plus Plasmid purification
kits, Promega), and the inserts were cycle-sequenced with
EP3-specific primers on an ABI373 automated sequencer
(Applied Biosystems, Warrington, UK). After removal of
plasmid sequences, the insert sequences were compared
with the database EP3 splice isoform sequences to confirm
identity with the best- fit algorithm.
Quantification of IL-6. IL-6 was measured with an
enzyme-linked immunosorbent assay.16
Immunohistochemistry. Aortic aneurysm sections
were prepared as described.5 Sections were preincubated
with biotin before sequential incubation with goat poly-
clonal antibodies to the EP4 receptors (Santa Cruz Bio-
technology, Santa Cruz, Calif) at 1:50 dilution and biotin-
ylated secondary antibody (Dako, Ely, England) at 1:250
dilution.
RESULTS
Secretion of IL-6 from aortic explants. After 96
hours in culture, aortic explants secreted large amounts of
IL-6, 355  41 ng/mL (n  11). In the presence of
indomethacin (10 mol/L), this volume was reduced to
105  16 ng/mL (P  .001; Table II). The simultaneous
addition of exogenous PGE2 or 11-deoxy PGE1 partially
reversed the indomethacin inhibition, whereas butaprost or
sulprostone had no effect (Table II). In contrast, addition
of dexamethasone completely suppressed IL-6 secretion.
Expression of EP2, EP3, and EP4 receptors in
aortic aneurysm tissue. With the nested primers for EP1
and EP2 receptors, fragments of 482 and 121 bp, respec-
tively, were expected. There was no evidence of the 482 bp
band for the EP1 receptor in cDNA from placenta, aorta,
HSB-2, or aortic SMC. A strong 121 bp band for the EP2
receptor was observed when cDNA from placenta or AAA
biopsy specimens was amplified (Fig 1). Most cDNA, in-
cluding that from placenta, HSB-2 cells, and SMC, also
yielded a visible first-round product of 371 bp (primers
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EP2-3F and EP2-2R). In contrast, no clear products were
amplified from genomic DNA with these primers. The
HSB-2 cell line was selected as a positive control for the
EP3 receptor.15 Amplification of cDNA from 106 HSB-2
cells, with nested primers (EP3-SF, EP3-1F, EP3-SR, EP3-
2R) theoretically capable of detecting six splice variants of
the EP3 receptor, yielded fragments of 108, 133, 134, and
227 bp (Fig 2). The 108, 134, and 227 bp fragments
correspond to the sizes predicted for the EP3-III, EP3-IV,
and EP3-1b splice variants, and the 133 bp variant probably
corresponds to EP3-II. The identity of EP2, EP3-1b, EP3-
II, and EP3-III bands were confirmed with sequencing. As
expected, no bands were amplified from genomic DNA
with these primers: intron 2 is very large.11 With the nested
primers (EP3-SF, EP3-1F, EP3-5R, EP3-6R) the pre-
dicted fragment of 108 bp for the EP3-III variant was
amplified with cDNA isolated from placenta and from one
of five AAA biopsy specimens (Fig 1). The EP4 receptor
was identified as a 479 bp product with cDNA prepared
from placenta and most (four of five) AAA biopsy speci-
mens (Fig 1). Macrophages in the intima of aneurysm
biopsy specimens stained positively for the EP4 receptor
(Fig 2).
Cultured aortic SMC express EP2 and EP3 recep-
tors. With the nested primers for EP1, there was no evi-
dence for expression of EP1 in human aortic SMC from
normal or aneurysmal aorta. With the nested primers for
EP2 the 121 bp band was detected. Four splice variants of
EP3 were detected (Fig 3), ie, EP3-III (108 bp), EP3-II
(133 bp), EP3-IV (134 bp) and EP3-Ib (227 bp) with the
nested primers shown in Table I. This latter isoform, EP3-
1b, was detected only in cells cultured from normal aorta
and not in cells cultured from aneurysmal aorta. The EP4
receptor was not detected.
Stimulation of IL-6 secretion from cultured aortic
SMC. Unstimulated human aortic SMC from normal
aorta did not secrete IL-6 into the culture medium (IL-6
0.5 pg/mL). After stimulation with IL-1 (5 ng/mL for 6
hours) the IL-6 concentration in the medium increased to
3.5  0.6 pg/mL (n  5; P  .001). In contrast, after
stimulation of cells with PGE2 (100 nmol/L) for 6 hours
the IL-6 in the culture media remained at less than 0.5
pg/mL (n  5). Similarly, IL-1 stimulation increased
IL-6 secretion from human aortic SMC from aneurysmal
aorta from less than 0.5 pg/L to 3.8  1.2 pg/mL (n 
3), but PGE2 evoked no such increase.
Stimulation of aortic macrophages with EP recep-
tor agonists. Isolated aortic macrophages (50,000 
5000) were cultivated for 48 hours in Cascademedium 231
(0.5 mL) containing 10 m of indomethacin in the pres-
ence or absence of PGE2, 11-deoxy-PGE1, butaprost, or
sulprostone. Addition of PGE2 or 11-deoxy-PGE1 in-
creased IL-6 secretion (Table III).
DISCUSSION
The diverse actions of prostaglandins are a consequence
of binding to specific cell-surface prostanoid receptors. The
biologic functions mediated by PGE2 may be particularly
diverse, because there are four separate receptors, ie, EP1,
EP2, EP3, and EP4.8,9 Further complexity is provided by
the numerous splice variants of the EP3 receptor, each of
which may couple to a different cell-signaling pathway.11
With this diversity of receptors, it is possible that specific
receptor antagonists will provide safer, more selective drugs
than cyclooxygenase inhibitors. PGE2 is produced abun-
dantly by the diseased aortic wall, and it may have a pivotal
role in both the key cell and molecular mechanisms that
drive aneurysm expansion, inflammation, and proteoly-
sis.17 For example, PGE2 enhances secretion of IL-6, other
cytokines, and matrix metalloproteinases by means of in-
flammatory cells.15,17,18 In the diseased aortic wall, PGE2 is
synthesised principally through a COX2- dependent path-
way. COX2 is widely expressed in aneurysm wall, particu-
larly in macrophages and SMC.5 Using the available selec-
tive EP receptor agonists, we have shown that the PGE2–
stimulated IL-6 production by aneurysm wall appears to
require activation of the EP4 receptor. Expression of the
EP4 receptor was confirmed at RT-PCR, and immunohis-
tochemistry demonstrated staining of intimal macro-
phages. In contrast, SMC cultured from aneurysm wall did
Table II. Interleukin-6 production by aortic explants
Explant in culture for 96 h n
IL-6 (ng/ml)
(mean  SEM) P
Control 11 355  41
10 mol/L indomethacin 11 105  16 .001*
10 mol/L indomethacin PGE2 (1 M) 8 188  13 .025
†
10 mol/L indomethacin 11-deoxyPGE1 (1 mol/L) 5 165  21 .05
†
10 mol/L indomethacin butaprost (1 mol/L) 5 113  18 .5†
10 mol/L indomethacin sulprostone (1 mol/L) 5 92  28 .5†
0.1 mol/L dexamethasone 8 10 .001
0.1 mol/L dexamethasone PGE2 (1 mol/L) 5 10 No difference from
0.1 mol/L
dexamethasone
PGE, Prostoglandin E.
*Comparison with control.
†Comparison with 10 mol/L indomethacin, Student paired t test.
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not respond to PGE2 with IL-6 secretion and did not
express the EP4 receptormRNA. Therefore it appears likely
that activation of EP4 receptors in other cell types, includ-
ing macrophages, is the principal mechanism underlying
PGE2 stimulation of IL-6 production by aortic aneurysm
wall.
Aortic explants remain viable for up to 1 week in
culture, and provide opportunity to study the complex
architecture of the aortic wall.18 The pharmacology of EP
receptor agonists in human beings has shown that butap-
rost is relatively selective for the EP2 receptor and that
sulprostone is relatively selective for the EP3 receptor,
because EP1 receptors are scant in human beings. 11-
Deoxy-PGE1 is primarily an agonist for both EP2 and EP4
receptors, with lower specificity for EP3 receptors.19 Of
these agonists, only 11-deoxy-PGE1 partially reversed in-
domethacin inhibition of IL-6 production by aortic ex-
plants or isolated macrophages, to indicate an EP4 receptor
Fig 1. Expression of EP2, EP3-III, and EP4 in abdominal aortic
aneurysm (AAA) biopsy specimens, showing placenta, aortic bi-
opsy tissue, and human aortic smooth muscle cell results in three
separate gels. Each gel has molecular weight markers in lane 1 and
a water control in lane 2.A, EP2: lane 3, placenta; lane 4, genomic
DNA; lane 5, placenta; lanes 6 through 8, samples from AAA
biopsy specimens. B, EP3: lanes as in A. C, EP4: lanes 3 through
6, samples from AAA biopsy specimens; lane 7, genomic DNA;
lane 8, placenta.
Fig 2. Expression of EP4 receptors in aortic aneurysm biopsy
specimen. Section through an aneurysmal wall, with lumen in top
right-hand corner. Large brown staining cells (macrophages) are
present predominantly in the atherosclerotic intima. Section coun-
terstained with hematoxylin.
Fig 3. Expression of EP3 variants in aortic smooth muscle cells,
showing range of variants in a single gel. Lane 1, molecular weight
markers; lane 2, HSB-2 cells; lane 3, normal human aortic smooth
muscle cells; lane 4, water control; lanes 5 through 6, human aortic
smooth muscle cells cultured from abdominal aortic aneurysm
(AAA) biopsy specimens; lane 7, genomic DNA; lanes 8 and 9,
human aortic smooth muscle cells cultured from AAA biopsy
specimens.
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pathway. We used fixed saturating concentrations of ago-
nists, and did not use a range of concentrations to deter-
mine their efficacy (median effective concentration). There
were two reasons for this: limited amounts of biopsy mate-
rial and the wide range of IL-6 production by explant
cultures reflecting pathobiologic variation. However, EP4
receptor was expressed in AAA tissue, together with EP2
and EP3-III, and EP4 protein was associated with macro-
phages in the aortic wall. In contrast, SMC cultured from
AAA wall did not express EP4 receptor mRNA and did not
secrete IL-6 in response to PGE2. This supports our sug-
gestion that EP4 receptors are important in mediating the
IL-6 response to PGE2 in the aneurysm wall.
We also noted complete suppression of IL-6 secretion
from aneurysm wall explants treated with dexamethasone.
Dexamethasone suppresses COX2 expression, but appears
to have variable effect on IL-6 expression, depending on
cell type.20-23 Dexamethasone also may suppress expres-
sion of EP receptors, but evidence for this is weak.24 Other
evidence indicates the presence of a positive feedback loop,
in which PGE2 stabilizes COX2 mRNA through an EP4-
dependent mechanism.25 However, exogenous PGE2 did
not reverse dexamethasone suppression, and therefore ex-
periments with synthetic agonists were not conducted.
The most elegant approaches to determine the differ-
ent pathobiologic effects of the four subtypes of EP recep-
tors have been based on use of genetically modified ani-
mals. For example, in an experimental murine model of
rheumatoid arthritis, deletion of EP1, EP2, or EP3 recep-
tors did not alter severity of the disease process.26However,
EP4 receptor–deficient mice demonstrated less severe dis-
ease, together with marked reduction in serum IL-6 con-
centration.26 Others have shown that the EP4 receptor
mediates IL-6 secretion in monocyte cell lines.23
Our findings support the importance of EP4 receptors
in inflammatory processes in the AAA wall and indicate a
more selective route for therapeutic intervention than non-
steroidal anti-inflammatory drugs, in developing a thera-
peutic strategy to limit the growth of small aneurysms.
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Table I, online only. Primers designed for amplification of EP receptors
Primer Sequence Sequence position
EP1-1F ATG GTC TTC TTC GGC CTG T 422-440 Exon ]
EP1-2R AAA GAA GGT GGA GGC CGA A 901-883 Exon ]
EP1-3F TGG TGC TGC GTC TGT ACA CT 354-373 Exon ]
EP1-4R TAG TCG TTG GGC CTC TGG TT 1306-1287 3 UTR ]
EP2-1F GAA ACC TCT TCC CGA AAG GA 1018-1037 Exon ]
EP2-2 TGA AAT CCG ACA ACA GAG GAC 1161-1141 Exon ]
EP2-3F GCC TGC AAC TTC AGT GTC ATT 793-813 Exon ]
EP2-4R CGC ATT AGT CTC AGA ACA GGA G 1136-1115 Exon ]
EP3-SF CTT AAT AGC TGT TCG CCT GG 983-1002 Exon 2
EP3-1F* CTG AAC CAG ATC TTG GAT CC 1008-1027 Exon 2
EP3-SR GGC AGA AAG GCA GGT TTT A 1464-1446 Exon 1 C
EP3-2R* TCA TGG AGC TTC CAG TGA TG 1491-1472 Exon 1 C
EP3-3 GAA GTT GGA AAC TCC TGG 1722-1702 Exon 4
EP3-4 TCC TCC AAT CAT CAT CTG TGA 1674-1654 Exon 4
EP3-5R TAC GAA TGG CAG ACT CAA CA 1632-1613 3 UTR
EP3-6R GAT AAT GAG ATA GGC TGC CCT 1497-1478 Exon 1 C
EP3-7R TCC AGA GAT GCA CTG CAT T 1783-1765 3 UTR
EP3-8R GCA GTC TTG GCA ATT CTG A 1725-1707 3 UTR
EP4-F† AGA CAC CTG GTG CTT CAT CG 885-904 Exon
EP4-R† GGT CTA GGA TGG GGT TCA CA 1363-1344 Exon
EP1, Base positions refer to Genbank accession number L22647.
EP2, Base positions refer to Genbank accession number NM000956.
EP3, Base positions refer to Genbank accession numbers D38297 (EP3-3 and EP3-4, EP3-5R, and EP3-6R); X83862.1 (EP3-7R and EP3-8R).
EP4, Base positions refer to Genbank accession number D28472.
*Primers designed by Kotani et al.9
†Primers designed by Paul et al.10
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